Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

1 Customer Review

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XmU|DjiJNzMECwJO69dQ>? NXz4RZFSOjRiaNMg NWK4Vos2cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NWm2[HdROjZyOEi3NVE>
POLK WT M4fVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXQTWM2OD1zMT635qCKyrIkgJmxMlfDqM7:TR?= MVyyOlA{OTRyMB?=
POLK KO M1TC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PBe2lEPTB;ND6wN-KBkcLz4pEJNU46OsLizszN NVz4N|NFOjZyM{G0NFA>
POLK CD NWDMVGZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTVwNUpihKnDueLCiUGuNFDDqM7:TR?= NXGx[G05OjZyM{G0NFA>
RLE/Abca3 NVX2UIpLTnWwY4Tpc44hSXO|YYm= Ml7LNE41yqEQvF2= MoLtNVQ1yqCq NEPXemRqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg NHL1O28zPTd4MEWzPC=>
PMCs MmPDSpVv[3Srb36gRZN{[Xl? M2\KSFAvOeLCk{NCpO69\y:vbB?= NUf0SnFDOjUEoHi= M1HNboNifXOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;0[YlvKGyndnXsJI9nKGOxbHzh[4VvNUoEoB?= MU[yOVU6PTZ2Mh?=
PMCs NHm5bHpHfW6ldHnvckBCe3OjeR?= M2nWOFAvOsLizsznM41t NGHqfowzPOLCk{eyxsBp NYHSOJV2cW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw NHXSfoEzPTV7NU[0Ni=>
PMCs M1KyUWZ2dmO2aX;uJGF{e2G7 NIrKSGoxNjMEoN88[{9udA>? NIfzZZE4OiCq NUC4bo5mcW6mdXPld{Bl\WO{ZXHz[ZMhcW5iY4n0c4tmemG2aX6tPEBidmRiRT3jZYRp\XKrbjDwdo91\Wmw NFn3NogzPTV7NU[0Ni=>
PMCs MkX2SpVv[3Srb36gRZN{[Xl? MnPiNE4zyqEQvHevcYw> NF\t[YwyOi9{ND:0PEBp NVvGTII5cW6lcnXhd4V{KGOnbHygcYloemG2aX;u M1fV[|I2PTl3NkSy
IMR-32 NYfJbZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjo[Fg4NjYkiKKxNlAhyrWpL33s NXnIT5VXOTMkiKK0PEBp NGLNTJJKSzVyPU[wJOK2\y:vbDDheEB1cGViZX7kJI9nKDJ2IHjyd{Bw\iCrbnP1ZoF1cW:w NWryR3djOjV3M{[zOFU>
HT1080 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxJO69VQ>? NULzT3RKOjRiaNMg NF\EeJNt\WGmczD0c{BiKEd{L12g[IVt[Xl? NH\KU|MzPTVzOEm2NS=>
HT1080 MoXHSpVv[3Srb36gRZN{[Xl? NV;xeWxPOSEQvF2= MYKyOEBpyqB? NULsNml{cW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> NXS5WpV7OjV3MUi5OlE>
HDFn M3\LNmN6fG:2b4jpZ4l1gSCDc4PhfS=> NU\YdHNYPzJiaB?= NYLI[HlZUUN3ME25MlMyLcLi M2DrOFI2Ojd4N{my
THP-1 NYLndpdxS3m2b4TvfIlkcXS7IFHzd4F6 M1\x[FczKGh? NGXjVmJKSzVyPUSuO|cm M2jCPFI2Ojd4N{my
HT-29 NIfGcodEgXSxdH;4bYNqfHliQYPzZZk> NFHaZ204OiCq MnvOTWM2OD1zMT60PUU> MlTXNlUzPzZ5OUK=
HCT116  NWPv[VVNS3m2b4TvfIlkcXS7IFHzd4F6 NGTvZXQ4OiCq MoLTTWM2OD1zMT6zOEU> MnPtNlUzPzZ5OUK=
A431 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[1NE0zODBiSWW= MVu0PQKBkWh? NIjuSZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVfzNHI6OjVzMEGyPVk>
T24 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV21NE0zODBiSWW= NH7YdZM1QOLCiXi= NHvwXlBqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MWeyOVExOTJ7OR?=
AY-27  NVnSW3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n1VFUxNTJyMDDJWS=> NEHRfW01QOLCiXi= NUjNR205cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mn61NlUyODF{OUm=
A549 MnntSpVv[3Srb36gRZN{[Xl? NIruepQyKML3Zz;tUOKh MV6wMVQ5KGh? MVvpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MXeyOFk3OzZ|NR?=
MLE12 NF3TPWVHfW6ldHnvckBCe3OjeR?= MXuxJOK2\y:vTNMg MXWwMVQ5KGh? NIG0cZNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? MYiyOFk3OzZ|NR?=
Jurkat Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nycVIx6oDLzszt M1TCVVI16oDLaNMg NYjGNWRE[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NUHhNVNKOjR7MU[4PVM>
HeLa  M{\pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfrTWM2OD1zMD6yxsDPxE1? MnniNlQ4OzJ|OUe=
C18-4 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fQS|AuOTByIN88US=> NVzaO3JwcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NFHrOIgzPDV5MUm4Ni=>
BMG-1  M{H1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG0NE85OMLizsznM40> MnjYN:KhcA>? NV3hdmI6cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NEOxOnUzOzlyNkeyOi=>
A459 MVLBdI9xfG:|aYOgRZN{[Xl? NYr3WGF3OTBibWW= NVnXWG1kPDhiaB?= M2XkNYlv\HWlZYOgZZBweHSxc3nz NHfJNZUzOzlyMke2Oi=>
MOCK NFu4OmpCeG:ydH;zbZMhSXO|YYm= MYSxNEBuXQ>? NV3hN5hIPDhiaB?= M{XQSIlv\HWlZYOgZZBweHSxc3nz NF3wcnEzOzlyMke2Oi=>
MMP1 M3jBV2Fxd3C2b4Ppd{BCe3OjeR?= Mn7WNVAhdVV? MUm0PEBp MULpcoR2[2W|IHHwc5B1d3Orcx?= MnPGNlM6ODJ5Nk[=
A549 NUHNZ|JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X3VVIxOCEQvF2= NFe0ZXMzPCCqwrC= MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> Mof0NlM5ODV5OUO=
HCT-116 Mlr1RZBweHSxc3nzJGF{e2G7 MX6zM|cvPS9zNTFOwIcwdWx? MoDuOFghcA>? M1P6WZJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> NIj2WFIzOzdyOE[2PC=>
HeLa MmXkRZBweHSxc3nzJGF{e2G7 MkjuN{84NjVxMUWg{txoN22u NFXhb2o1QCCq Mnq0doVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> Mn7rNlM4ODh4Nki=
HCT116 NVTENFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfpNGsxNTFyMDFOwIcwdWx? MnfkOFghcA>? NYT0S|d[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVeyN|UyQDJyMR?=
NCM460 NVrYSWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqV3UxNTFyMDFOwIcwdWx? M2\hfFQ5KGh? NF\ITFlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmfwNlM2OTh{MEG=
NT2  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnWS4MzPCCqwrC= MUfMSFUxRTRyMPMAjeK2\y:vbB?= M3ewNlI{Ozh4NEKw
NT2  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0PEBp NX;pXoJnVER3ME2xNFAhyrWpL33s M4m2[VI{Ozh4NEKw
NT2  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LhNFczKGh? NV\vWZdiVER3ME2yNQKBkcL3Zz;tcC=> M1PtTVI{Ozh4NEKw
NT2  M4fuZmFxd3C2b4Ppd{BCe3OjeR?= MYK0NFDjiIoEtXevcYw> MkLRNlQhcMLi M3LiT4lv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? Mn\4NlM{QDZ2MkC=
NTera-2 NHvMRXJHfW6ldHnvckBCe3OjeR?= MVOxNlAh|rypL33s MnzYO|IhcA>? MYHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyB6LXnzc5Bzd3O2YX7lJIxmfmWucx?= NFP6cmgzOjh{NUO1OS=>
NCCIT NYm5flZJTnWwY4Tpc44hSXO|YYm= NITIXZIyOjBizsznM41t MWW3NkBp M1\NUJNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz M4fl[|IzQDJ3M{W1
NTera-2 Ml3RSpVv[3Srb36gRZN{[Xl? MVGxNlAh|rypL33s M1fs[FczKGh? NXPSN5hPe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ M{\l[VIzQDJ3M{W1
NCCIT M1THXGZ2dmO2aX;uJGF{e2G7 NYi4Xo51OTJyIN88[{9udA>? NFXOSWY4OiCq NF:3UoJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MnSxNlI5OjV|NUW=
NCCIT Mnz2SpVv[3Srb36gRZN{[Xl? NFvMfJQyOjBizsznM41t MkK5O|IhcA>? MXzzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| M1fQflIzQDJ3M{W1
NTera-2 MnXYSpVv[3Srb36gRZN{[Xl? MWOxNlAh|rypL33s Mlf6O|IhcA>? NF\YOW5{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? M1ThSFIzQDJ3M{W1
NCCIT NXTMTZo3TnWwY4Tpc44hSXO|YYm= NXrGPZp[OTJyIN88[{9udA>? NVvKSHBsPzJiaB?= MojVd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MorJNlI5OjV|NUW=
NTera-2 MonkSpVv[3Srb36gRZN{[Xl? MWWxNlAh|rypL33s MXK3NkBp Mn;od4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= NVvtZYM6OjJ6MkWzOVU>
NCCIT M3vmTmZ2dmO2aX;uJGF{e2G7 MYixNlAh|rypL33s M3TqXlczKGh? NVzkbo1Qe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MYWyNlgzPTN3NR?=
MDA-MB-468 M3LZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mxO|DjiJN{MEFCpO69\y:vTB?= M2\B[|I1KGh? MlS5bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUDj[FdMOjJ6MUmxPVY>
231-H2N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG5NWF1OOLCk{KwNOKh|rypL33M NG\0R3czPCCq NUXDNWRxcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVSyNlgyQTF7Nh?=
A549  NUDZdY5sTnWwY4Tpc44hSXO|YYm= M3;uR|IxOC92MECg{txO MVvy[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= Mo[2NlI4PzN4OUe=
A549  NHm0N4NHfW6ldHnvckBCe3OjeR?= M4Dzd|AuPDByIN88US=> NXrrOGRkOi12ODDo M3rKboNifXOnczDtc5JmKG22RF7BJJRp[W5iblTORUBl[W2jZ3W= MoH4NlI4PzN4OUe=
A549  MmPvSpVv[3Srb36gRZN{[Xl? MnnpNVAxKM7:TdMg M4qyXFDjiJN2ODDo NXzuPYNt[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v Ml:zNlI4PzN4OUe=
A549  NXXIfotYTnWwY4Tpc44hSXO|YYm= MYixNFAh|ryPwrC= MYCw5qCUPDhiaB?= MULjZZV{\XNiUFvENUBkdGWjdnHn[S=> MmfzNlI4PzN4OUe=
A549  MojXSpVv[3Srb36gRZN{[Xl? MojDNVAxKM7:TdMg NIW4TYYx6oDVNEigbC=> NIr5bHdk[XW|ZYOgcYl1d2Oqb37kdolidCCub3PhcIl7[XSrb36gc4YhSmG6 NFztZXozOjd5M{[5Oy=>
A549  M2TqSmZ2dmO2aX;uJGF{e2G7 NFfXPXQyODBizszNxsA> M4HqblDjiJN2ODDo NE\4NIdl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ MljzNlI4PzN4OUe=
MCF-7/Her-18  M136SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3Oow1OC52Mj2xO|AxKM7:Zz;tUC=> MkjwNlQhcA>? MmX6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXHSOZZzOjJ4MkG0NFQ>
MCF-7 MofVVGRVN1CFSTDUdoVifG2nboS= NET6c2IxNjJ3IN88[{9udC5? M3T2d|EuPCCq MnKwd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> M{G0dFIzPTlzMki0
MDA-MB-231 NHLyTFVRTFRxUFPJJHRz\WG2bXXueC=> NGjzeosxNjJ3IN88[{9udC5? MlTDNU01KGh? NHjPfFJ{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NXT1T|lmOjJ3OUGyPFQ>
MDA-MB-235  NI\kWGhRTFRxUFPJJHRz\WG2bXXueC=> NW\SN2pyOC5{NTFOwIcwdWxw NV\BNJNjOS12IHi= M364[5Npd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> NEjKOngzOjV7MUK4OC=>
MCF-7 NYfBe3RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vwOVAuOiEQvHevcYwv Mor0NlQwPDhiaB?= NEHqeoFGSzVyPUGuNkDPxGdxbVy= NYLjSHhLOjJ3OUGyPFQ>
NCCIT  NIHxSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTIWnIzOOLCk{G0NOKh|rypL33s NVTqSIszPzJiaB?= NFjVOXZNTDVyPUGyNOKh|rypL33sxsA> M1j1TFIzPTZ{MU[w
NCCIT  NFX0cIRHfW6ldHnvckBCe3OjeR?= Ml;EO|IhcA>? M2L3dZNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzDhZ5Rqfmm2edMg MWCyNlU3OjF4MB?=
NCCIT  NHHQOnlHfW6ldHnvckBCe3OjeR?= MmPjO|IhcA>? NEPGTFF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> NWjkSFk3OjJ3NkKxOlA>
NCCIT  MlTtSpVv[3Srb36gRZN{[Xl? NWniOnd3PzJiaB?= MkPYd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S17IHHjeIl3cXS7wrC= NGrORpAzOjV4MkG2NC=>
NCCIT  MWrGeY5kfGmxbjDBd5NigQ>? MmXlO|IhcA>? MVrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NX7QPWN5OjJ3NkKxOlA>
NCCIT  NIn2bXFHfW6ldHnvckBCe3OjeR?= MofIO|IhcA>? M1nlXZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBD[2xvMjDjc451\W62 M1nDS|IzPTZ{MU[w
NCCIT  NEDHeZZHfW6ldHnvckBCe3OjeR?= NGXRVY84OiCq NGDVSIJ{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhS3m2LXOgcIV3\Wx? NEnWbIkzOjV4MkG2NC=>
HeLa NVX3TnpSTnWwY4Tpc44hSXO|YYm= M{jheFMxNzdyIN88[{9udA>? M4HBVlI1yqCq MXrpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> Mn3oNlI1QDd7M{e=
MCF-7  NVHrSo9{TnWwY4Tpc44hSXO|YYm= M3G3ZVMxNzdyIN88[{9udA>? NGfWcoczPMLiaB?= MVvpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NXPBbpdFOjJ2OEe5N|c>
HeLa Mo\PR5l1d3SxeHnjbZR6KEG|c3H5 MkHkN|AwPzBizsznM41t NF7MdVAzPMLiaB?= MknpbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv MUGyNlQ5Pzl|Nx?=
MCF-7  NGHUdWdEgXSxdH;4bYNqfHliQYPzZZk> M3uweVMxNzdyIN88[{9udA>? MYWyOOKhcA>? Mn;SbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv NHe3SYEzOjR6N{mzOy=>
NT2 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrrNVAxNTZyMNMg{txoN22u NXnYPZhoOjRiaB?= NIfqWoZKSzVyPUSwNEDDvWdxbXy= NX;4SHNkOjJ2Nkm5OVI>
NT2 M3z6UGZ2dmO2aX;uJGF{e2G7 MoLMOFAxyqEQvHevcYw> NX3nfYtSOjRiaB?= Mnzzd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh NIjMbW0zOjR4OUm1Ni=>
NT2 MYPGeY5kfGmxbjDBd5NigQ>? NETueGc1ODEEoN88[{9udA>? NX;ScJE4OjRiaB?= NWXzVFlSe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs M4n0XVIzPDZ7OUWy
NT2 NFrIXYVHfW6ldHnvckBCe3OjeR?= NXjve5BNPDBywrFOwIcwdWx? MWKyOEBp NH3vbHd{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> MYSyNlQ3QTl3Mh?=
CHO MVzGeY5kfGmxbjDBd5NigQ>? NV7DXJkyOi53wrFOwIcwdWx? NUjae3RCOThiaD:2JIQ> MVXpcoR2[2W|wrDw[ZJ{cXO2ZX7j[UBw\iClaILvcY9{d22nIHThcYFo\Q>? M12xU|IzOjNyMUm1
Jurkat MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLY[XQxNTFyMNMg{txoN22u M1rIdlI1KGh? NUjWdZhM[XK{ZYP0d{B1cGViY3XscEBkgWOuZTDheEB1cGViR{KgdIhie2V? NGXaTW0zOjJ{M{OzNi=>
Jurkat NF3nUoxHfW6ldHnvckBCe3OjeR?= NHzRNoU{OMLizsznM41t NVnLPFBjOjRiaB?= MUTpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKGO7Y3zpcpMhTDNuIFGgZY5lKEJz NHrxbGczOjJ{M{OzNi=>
Jurkat MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X3RVAuOTBywrFOwIcwdWx? M3\FOlI1KGh? MojLbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? M37IWFIzOjJ|M{Oy
Jurkat M3HvU2Z2dmO2aX;uJGF{e2G7 NInJ[lI{OMLizsznM41t M3r2TFI1KGh? MWnpcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? NGX0WlMzOjJ{M{OzNi=>
U2OS EGFPnls M{fG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjRN3d1OC1{wrFOwIcwdWx? Mk[1NlQhcA>? M1LsRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXjl[nJ3OjF6MUGwNFc>
U2OS KuEnls M2DYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmwMVLDqM7:Zz;tcC=> NYPDOZNlOjRiaB?= MVnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NFfjOoczOThzMUCwOy=>
MCF-7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz6NE01ODBizszN NGrF[po4OiCq NETXW25NSzVyPUG1NU45yqEQvF2= NFfseokzOTdyM{K5NS=>
MCF-7/Adr  Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7ES2VrOC12MECg{txO MVS3NkBp MXnMR|UxRTV6LkZCpO69VcLi MUmyNVcxOzJ7MR?=
WI-38 NUT6eld2TnWwY4Tpc44hSXO|YYm= NYDhb3FxOC92MD:4NQKBkc7:Zz;tcOKh M3XsRlMhcA>? Mk[wbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MVGyNVU6QTZzMh?=
hBMSC NVft[JcyTnWwY4Tpc44hSXO|YYm= NVHwNJJSOC92MD:4NQKBkc7:Zz;tcOKh MoLNN{Bp NH25V4hqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh M3fGb|IyPTl7NkGy
NCI-H23 NYP5TlV1TnWwY4Tpc44hSXO|YYm= NHG3cngxNzRyL{iw5qCK|rypL33sxsA> NX7LeXNNOyCq NI\YUpRqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NX3yRZg2OjF3OUm2NVI>
A-549 M17BN2Z2dmO2aX;uJGF{e2G7 MnnuNE81OC96MPMAje69\y:vbNMg MUizJIg> M2O5Volv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NX\MRo5EOjF3OUm2NVI>
PBL  M{DwOmZ2dmO2aX;uJGF{e2G7 MXuwM|QxNzhy4pEJ{txoN22uwrC= NGPkdlc{KGh? M32xc4lv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NUG2dIsxOjF3OUm2NVI>
pol β −/− MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30cmYxNjJ3LUKwNOKh|rypL33s MorqNlTDqGh? Mn3i[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh NVXUS2RFOjF{NUG5OFQ>
pol β +/+ NIK5c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ad2ZxOC5{NT2yNFDDqM7:Zz;tcC=> M2nGUVI1yqCq MUnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> Mn;LNlEzPTF7NES=
pol β −/− MXLGeY5kfGmxbjDBd5NigQ>? MXewMVIvPSEQvHevcYw> NYTZSGY3OiCq M3[wRYNifXOnczDEUmEh\GGvYXfl MlLzNlEzPTF7NES=
pol β +/+ M4LY[GZ2dmO2aX;uJGF{e2G7 Mkm0NE0zNjVizsznM41t NHXwUJMzKGh? NYD3N4JU[2G3c3XzJGRPSSCmYX3h[4U> NVnYTFloOjF{NUG5OFQ>
pol β −/− NHfRNHRHfW6ldHnvckBCe3OjeR?= MYWwMVUh|rypL33s MWe0PEBp NHTIT5hk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NGi2ZpkzOTJ3MUm0OC=>
pol β +/+ MYPGeY5kfGmxbjDBd5NigQ>? MkjmNE02KM7:Zz;tcC=> M{ThWlQ5KGh? NFvqfodk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NXTXUIJnOjF{NUG5OFQ>
TK6  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\iclkzPS1zNUCg{txoN22u M2LYTFk3KGh? MVfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoPqNlExQDF2OEe=
TK6  sLUC+Apn1 NITU[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm0NlUuOTVyIN88[{9udA>? M{\RXVk3KGh? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXyyNVA5OTR6Nx?=
TK6 sAPE1+Apn1 NXK3PHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\CdlI2NTF3MDFOwIcwdWx? MkfWPVYhcA>? NVW4R4Nbe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MYqyNVA5OTR6Nx?=
HCT116 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXeyOU0yPTBizsznM41t NXKx[Y9DQTZiaB?= Ml7ObY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWqyNVA5OTR6Nx?=
HCT116 sLUC+Apn1 M1;Qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPY[oUzPS1zNUCg{txoN22u NUfIdmlVQTZiaB?= M1:5ZolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M2frcVIyODhzNEi3
HCT116 sAPE1+Apn1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyyOU0yPTBizsznM41t NF\GU4U6PiCq M{PxNpNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= M3joOlIyODhzNEi3

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID